Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer
- Conditions
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- Hospital Authority, Hong Kong
- Target Recruit Count
- 798
- Registration Number
- NCT00577057
- Locations
- 🇨🇳
Tuen Mun Hospital, Hong Kong, China
🇨🇳Prince of Wales Hospital, Hong Kong, China
🇨🇳Pamela Youde Nethersole Eastern Hospital, Hong Kong, China
Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 29
- Registration Number
- NCT00574171
- Locations
- 🇺🇸
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States
Brain Mets - Capecitabine Plus Sunitinib and WBRT
- Conditions
- Interventions
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Baylor Breast Care Center
- Target Recruit Count
- 12
- Registration Number
- NCT00570908
- Locations
- 🇺🇸
Lester and Sue Smith Breast Center at Baylor College of Medicine, Houston, Texas, United States
A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2016-03-10
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 9
- Registration Number
- NCT00568022
- Locations
- 🇯🇵
Local Institution, Osaka, Japan
Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery
- Conditions
- Interventions
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT00562718
- Locations
- 🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection
- Conditions
- Interventions
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2010-07-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 290
- Registration Number
- NCT00561522
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2011-05-16
- Target Recruit Count
- 200
- Registration Number
- NCT00559676
- Locations
- 🇫🇷
Centre Hospital Regional Universitaire de Limoges, Limoges, France
Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-11-08
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 76
- Registration Number
- NCT00555620
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
- Conditions
- Interventions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 67
- Registration Number
- NCT00551213
Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2013-12-25
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 23
- Registration Number
- NCT00551096
- Locations
- 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.